The last time was March 27, when Valeant Pharmaceutical was added, hence the update.

FORBES: Preying on an Easy Mark

Not allowed to perform proper due-diligence, Valeant has not announced what possible synergies would derive from the merger.

FORBES: Valeant Takes $5.7B Bid For Cephalon Directly To Shareholders

Valeant Pharmaceuticals International Inc is trading up about 0.1% on the day Thursday.

FORBES: Thursday 3/14 Insider Buying Report: NVAX, VRX

Valeant will host a conference call and a live Internet webcast along with a slide presentation on Tuesday, September 4, 2012 at 8:00 a.m.

FORBES: Valeant To Acquire Medicis for $2.6 Billion

There was some excitement that Actavis could be acquired by either Valeant or Mylan and thus trigger a wave of additional larger-scale combinations focused on the generic space.

FORBES: Three Reasons Actavis Is Buying Warner Chilcott

Valeant Pharmaceuticals (VRX) is commercializing the treatment.

FORBES: Pharma News: Alexza Pharmaceuticals, YM BioSciences

Valeant said ISTA refused to enter into a confidentiality agreement when it first approached the company about an acquisition in October, and subsequently rejected a written proposal, so Valeant has decided to make an unsolicited offer to shareholders.

FORBES: Pharma News: Valeant Bids for ISTA, Pfizer Announces Study Results, Vaccine Pact

Shares in Valeant opened up 12%.

FORBES: Private Jobs Added: ADP Report Lower Than Expected

On the other hand, as a serial acquirer, if Valeant simply adds Medicis, and then looks for its next deal without taking care to truly integrate Medicis and manage it well, this could turn out to be a benefit to competitors like Allergan.

FORBES: Valeant To Acquire Medicis for $2.6 Billion